This is a table of type proper and their frequencies. Use it to search & browse the list to learn more about your study carrel.
| proper | frequency |
|---|---|
| HCQ | 4408 |
| COVID-19 | 2947 |
| SARS | 1889 |
| CQ | 1701 |
| el | 1538 |
| CoV-2 | 1337 |
| los | 886 |
| Hydroxychloroquine | 749 |
| con | 682 |
| para | 601 |
| del | 539 |
| un | 497 |
| azithromycin | 429 |
| pacientes | 415 |
| las | 403 |
| una | 394 |
| mg | 383 |
| hydroxychloroquine | 377 |
| Chloroquine | 373 |
| en | 369 |
| Coronavirus | 311 |
| China | 285 |
| Se | 279 |
| como | 279 |
| CoV | 277 |
| por | 262 |
| QTc | 222 |
| PCR | 206 |
| es | 203 |
| uso | 202 |
| recomienda | 189 |
| ACE2 | 189 |
| RNA | 185 |
| Disease | 184 |
| QT | 177 |
| La | 172 |
| meta | 168 |
| SLE | 166 |
| MERS | 166 |
| Table | 162 |
| su | 155 |
| IL-6 | 153 |
| ICU | 153 |
| AZ | 153 |
| CC | 148 |
| ventilación | 147 |
| Azithromycin | 145 |
| Wuhan | 145 |
| ECG | 145 |
| Treatment | 144 |
| puede | 143 |
| Health | 139 |
| BY | 138 |
| remdesivir | 135 |
| T | 135 |
| FDA | 132 |
| EC | 127 |
| ser | 126 |
| paciente | 126 |
| RA | 125 |
| medRxiv | 122 |
| Remdesivir | 118 |
| PK | 118 |
| LPV | 118 |
| Covid-19 | 117 |
| tratamiento | 115 |
| ND | 115 |
| J | 115 |
| AZM | 115 |
| AMCI | 115 |
| diagnóstico | 113 |
| UCI | 111 |
| riesgo | 109 |
| lo | 109 |
| estudios | 109 |
| enfermedad | 109 |
| NC | 109 |
| Fig | 107 |
| El | 107 |
| mortalidad | 106 |
| estudio | 105 |
| debe | 105 |
| Patients | 104 |
| más | 102 |
| ms | 101 |
| ritonavir | 99 |
| chloroquine | 99 |
| Clinical | 98 |
| manejo | 97 |
| March | 97 |
| Review | 96 |
| se | 95 |
| C | 93 |
| IFN | 92 |
| pH | 91 |
| II | 91 |
| días | 91 |
| June | 90 |
| Mpro | 89 |
| HIV | 89 |
| sha | 88 |
| RT | 88 |
| SDRA | 87 |
| New | 87 |
| mecánica | 86 |
| Drug | 85 |
| Syndrome | 85 |
| sospecha | 83 |
| France | 83 |
| AZI | 83 |
| entre | 80 |
| May | 79 |
| Supplementary | 78 |
| CI | 78 |
| kg | 77 |
| Respiratory | 77 |
| han | 76 |
| United | 75 |
| CT | 75 |
| States | 75 |
| S | 75 |
| sobre | 74 |
| mayor | 74 |
| Use | 74 |
| Study | 74 |
| Los | 74 |
| A | 73 |
| casos | 73 |
| endosomal | 73 |
| lopinavir | 73 |
| pulmonar | 73 |
| intubación | 73 |
| alta | 72 |
| pueden | 71 |
| esta | 71 |
| cuidados | 70 |
| RCT | 70 |
| Effect | 69 |
| ARDS | 69 |
| DOI | 69 |
| grupo | 69 |
| respiratoria | 69 |
| Vero | 68 |
| AEs | 68 |
| USA | 67 |
| Association | 67 |
| ivermectin | 66 |
| fue | 66 |
| Care | 66 |
| presión | 65 |
| personal | 65 |
| L | 64 |
| día | 64 |
| TNF | 63 |
| Efficacy | 63 |
| April | 63 |
| evidencia | 62 |
| Trial | 62 |
| World | 61 |
| tiempo | 60 |
| infección | 60 |
| este | 60 |
| IC | 60 |
| York | 59 |
| India | 58 |
| Hospitalized | 58 |
| salud | 57 |
| clínico | 57 |
| US | 57 |
| Organization | 56 |
| Therapy | 55 |
| Research | 55 |
| Middle | 55 |
| clínica | 55 |
| horas | 55 |
| • | 55 |
| soporte | 54 |
| menor | 54 |
| Gautret | 54 |
| National | 52 |
| E6 | 52 |
| B | 52 |
| RR | 51 |
| CoV-1 | 51 |
| East | 51 |
| M | 51 |
| Novel | 51 |
| Systematic | 51 |
| bajo | 51 |
| cols | 51 |
| síntomas | 51 |
| tocilizumab | 51 |
| protección | 50 |
| fueron | 50 |
| cuenta | 50 |
| alto | 50 |
| Lopinavir | 50 |
| Figure | 50 |
| Ebola | 50 |
| Outcomes | 49 |
| Italy | 49 |
| Las | 49 |
| pero | 49 |
| si | 49 |
| vivo | 48 |
| methotrexate | 48 |
| covid-19 | 48 |
| antiphospholipid | 48 |
| Society | 48 |
| COVID19 | 48 |
| atención | 47 |
| realizar | 47 |
| dosis | 47 |
| CoV2 | 46 |
| deben | 46 |
| contra | 46 |
| respiratorio | 46 |
| hasta | 46 |
| nivel | 46 |
| son | 46 |
| α | 45 |
| oxigenación | 45 |
| inicio | 45 |
| compromiso | 45 |
| clínicos | 45 |
| aguda | 45 |
| Tp | 45 |
| Plasmodium | 45 |
| Administration | 45 |
| intensivos | 44 |
| SProtein | 44 |
| TMPRSS2 | 44 |
| Cochrane | 44 |
| oxígeno | 44 |
| pandemia | 44 |
| ® | 44 |
| colchicine | 43 |
| HIV-1 | 43 |
| Randomized | 43 |
| Wang | 43 |
| niveles | 43 |
| críticos | 43 |
| severa | 43 |
| mejoría | 43 |
| Medical | 42 |
| COVID | 42 |
| Cardiac | 42 |
| July | 42 |
| En | 42 |
| RCTs | 42 |
| cual | 42 |
| otros | 42 |
| vía | 42 |
| terapia | 41 |
| seguridad | 41 |
| S1 | 41 |
| November | 41 |
| Cov-2 | 41 |
| Food | 40 |
| R | 40 |
| Safety | 40 |
| TLR | 40 |
| todos | 40 |
| resultados | 40 |
| Meta | 39 |
| Analysis | 39 |
| De | 39 |
| L. | 39 |
| IL-1 | 39 |
| PD | 39 |
| RMD | 39 |
| ingreso | 39 |
| pronóstico | 39 |
| torsade | 39 |
| severo | 38 |
| recursos | 38 |
| preprint | 38 |
| Prevention | 38 |
| American | 38 |
| Infection | 37 |
| CD4 | 37 |
| Control | 37 |
| recibieron | 37 |
| Assessment | 37 |
| Antiviral | 37 |
| Medicine | 37 |
| Ivermectin | 37 |
| utilizar | 37 |
| Nos | 37 |
| decisiones | 37 |
| dos | 37 |
| estrategia | 37 |
| falla | 37 |
| convaleciente | 37 |
| University | 36 |
| LQT | 36 |
| Observational | 36 |
| RDV | 36 |
| Tocilizumab | 36 |
| Yao | 36 |
| baja | 36 |
| donde | 36 |
| durante | 36 |
| número | 36 |
| realización | 36 |
| tipo | 36 |
| Sars | 35 |
| EPP | 35 |
| Hcq | 35 |
| Risk | 35 |
| S. | 35 |
| S2 | 35 |
| flujo | 35 |
| crítico | 35 |
| hipoxemia | 35 |
| manera | 35 |
| sido | 35 |
| sugiere | 35 |
| ± | 35 |
| Ritonavir | 34 |
| AE | 34 |
| Breakthrough | 34 |
| C. | 34 |
| FBX | 34 |
| cuales | 34 |
| desde | 34 |
| equipo | 34 |
| menos | 34 |
| posición | 34 |
| International | 33 |
| December | 33 |
| FIPV | 33 |
| Heart | 33 |
| Hospital | 33 |
| vida | 33 |
| PubMed | 33 |
| control | 33 |
| estos | 33 |
| tiene | 33 |
| considerar | 33 |
| TCZ | 32 |
| Activity | 32 |
| Diseases | 32 |
| Interval | 32 |
| PTX | 32 |
| Por | 32 |
| Q | 32 |
| Intensive | 32 |
| condiciones | 32 |
| diferentes | 32 |
| necesario | 32 |
| recomendaciones | 32 |
| reducción | 32 |
| severidad | 32 |
| criterios | 32 |
| disponibilidad | 31 |
| CYP | 31 |
| D | 31 |
| ECMO | 31 |
| IQR | 31 |
| cuando | 31 |
| luego | 31 |
| efectos | 31 |
| lesión | 31 |
| sin | 31 |
| traslado | 31 |
| utilización | 31 |
| ya | 31 |
| F | 30 |
| M. | 30 |
| MS | 30 |
| CRP | 30 |
| MD | 30 |
| medidas | 30 |
| RBD | 30 |
| así | 30 |
| síndrome | 30 |
| recomendación | 30 |
| Virus | 30 |
| Pointes | 29 |
| Data | 29 |
| Liu | 29 |
| Med | 29 |
| PEEP | 29 |
| Science | 29 |
| aerosoles | 29 |
| complicaciones | 29 |
| consentimiento | 29 |
| hospitalaria | 29 |
| procedimiento | 29 |
| respuesta | 29 |
| cada | 28 |
| Chen | 28 |
| MHC | 28 |
| Si | 28 |
| algunos | 28 |
| aérea | 28 |
| Dosing | 28 |
| decisión | 28 |
| estándar | 28 |
| evaluar | 28 |
| sea | 28 |
| infecciones | 28 |
| disminución | 28 |
| Una | 27 |
| BID | 27 |
| Center | 27 |
| FUNDAMENTO | 27 |
| N | 27 |
| PBPK | 27 |
| Pandemic | 27 |
| Pharmacokinetics | 27 |
| State | 27 |
| VT | 27 |
| asociada | 27 |
| clínicas | 27 |
| ensayos | 27 |
| neumonía | 27 |
| plasma | 27 |
| solo | 27 |
| tanto | 27 |
| WHO | 27 |
| CYP2C8 | 26 |
| DOXY | 26 |
| Creative | 26 |
| Commons | 26 |
| IV | 26 |
| CPE | 26 |
| Brazil | 26 |
| < | 26 |
| FIP | 26 |
| volumen | 26 |
| Mechanisms | 26 |
| análisis | 26 |
| disminuir | 26 |
| evitar | 26 |
| medicamentos | 26 |
| nan | 26 |
| revisión | 26 |
| también | 26 |
| PBS | 26 |
| Vitro | 25 |
| COV-2 | 25 |
| COVID‐19 | 25 |
| Ca | 25 |
| Es | 25 |
| Management | 25 |
| Sjögren | 25 |
| Reviews | 25 |
| antes | 25 |
| favipiravir | 25 |
| información | 25 |
| médico | 25 |
| tener | 25 |
| teniendo | 25 |
| trabajo | 25 |
| aumento | 25 |
| Early | 24 |
| Li | 24 |
| Korea | 24 |
| Infectious | 24 |
| IGIV | 24 |
| Guidelines | 24 |
| Case | 24 |
| Design | 24 |
| Committee | 24 |
| Colchicine | 24 |
| CRS | 24 |
| APS | 24 |
| Pneumonia | 24 |
| PaO2 | 24 |
| momento | 24 |
| Reporting | 24 |
| intensivo | 24 |
| SC | 24 |
| servicios | 24 |
| según | 24 |
| parte | 24 |
| tomar | 24 |
| sus | 24 |
| efecto | 24 |
| burnetii | 24 |
| apoyo | 24 |
| anakinra | 24 |
| acuerdo | 24 |
| comité | 24 |
| IRB | 23 |
| S3 | 23 |
| Post | 23 |
| OC43 | 23 |
| J. | 23 |
| Group | 23 |
| Healthcare | 23 |
| HCoV | 23 |
| College | 23 |
| ATC | 23 |
| adversos | 23 |
| UK | 23 |
| beneficio | 23 |
| renal | 23 |
| eventos | 23 |
| fcwf-4 | 23 |
| hospitalizados | 23 |
| importante | 23 |
| informado | 23 |
| médica | 23 |
| través | 23 |
| uno | 23 |
| coronavirus | 23 |
| veces | 23 |
| Marseille | 22 |
| Lupus | 22 |
| TLR9 | 22 |
| NIH | 22 |
| HR | 22 |
| Institutional | 22 |
| CYP2D6 | 22 |
| H1N1 | 22 |
| Fuerte | 22 |
| FAERS | 22 |
| ClinicalTrials.gov | 22 |
| RECOMENDACIÓN | 22 |
| significativa | 22 |
| aire | 22 |
| kcal | 22 |
| asociado | 22 |
| tienen | 22 |
| sensibilidad | 22 |
| muestras | 22 |
| presencia | 22 |
| está | 22 |
| estrategias | 22 |
| elevación | 22 |
| debido | 22 |
| crítica | 22 |
| MOX | 21 |
| Un | 21 |
| Spain | 21 |
| Solidarity | 21 |
| Projection | 21 |
| anticuerpos | 21 |
| Molecular | 21 |
| Favipiravir | 21 |
| MOI | 21 |
| MOH | 21 |
| Journal | 21 |
| Guidance | 21 |
| Germany | 21 |
| CYP3A4 | 21 |
| Adults | 21 |
| adultos | 21 |
| Optimized | 21 |
| carga | 21 |
| objetivo | 21 |
| críticamente | 21 |
| tratados | 21 |
| toma | 21 |
| siguientes | 21 |
| requiere | 21 |
| reanimación | 21 |
| viral | 21 |
| necesidad | 21 |
| muestra | 21 |
| medición | 21 |
| invasiva | 21 |
| establecer | 21 |
| escala | 21 |
| multicentre | 21 |
| Institute | 20 |
| agudo | 20 |
| Zika | 20 |
| System | 20 |
| Para | 20 |
| N95 | 20 |
| Board | 20 |
| I | 20 |
| Chinese | 20 |
| CD8 | 20 |
| Bdnf | 20 |
| Associated | 20 |
| calidad | 20 |
| ante | 20 |
| disease | 20 |
| tasa | 20 |
| prueba | 20 |
| estado | 20 |
| siendo | 20 |
| sedación | 20 |
| rutinaria | 20 |
| residuos | 20 |
| punto | 20 |
| retrospectivo | 20 |
| presenta | 20 |
| mejor | 20 |
| mRNA | 20 |
| https://doi.org/10.1101/2020.11.01.20223958 | 20 |
| gestión | 20 |
| frecuencia | 20 |
| Kawasaki | 19 |
| Sharma | 19 |
| Prophylaxis | 19 |
| PRISMA | 19 |
| P. | 19 |
| Mechanism | 19 |
| Lancet | 19 |
| Unit | 19 |
| General | 19 |
| GMP | 19 |
| Crh | 19 |
| CoVs | 19 |
| CDC | 19 |
| Autophagy | 19 |
| AMP | 19 |
| Studies | 19 |
| evolución | 19 |
| Zhang | 19 |
| enfermo | 19 |
| rutina | 19 |
| asociación | 19 |
| incluyendo | 19 |
| https://doi.org/10.1101/2020.04.08.20054551 | 19 |
| factores | 19 |
| evaluaron | 19 |
| grupos | 19 |
| dificultad | 19 |
| contexto | 19 |
| desenlaces | 19 |
| dentro | 19 |
| curso | 19 |
| camas | 19 |
| deterioro | 19 |
| High | 18 |
| Human | 18 |
| IgM | 18 |
| Ill | 18 |
| Low | 18 |
| K | 18 |
| MAPK | 18 |
| Report | 18 |
| Foundation | 18 |
| Saudi | 18 |
| HCWs | 18 |
| Article | 18 |
| Evaluation | 18 |
| ER | 18 |
| Distress | 18 |
| Cox | 18 |
| Cell | 18 |
| CNS | 18 |
| Antimalarial | 18 |
| Al | 18 |
| AZN | 18 |
| AERS | 18 |
| Torsade | 18 |
| SpO2 | 18 |
| función | 18 |
| Yang | 18 |
| otras | 18 |
| � | 18 |
| ≥ | 18 |
| adecuado | 18 |
| sistemática | 18 |
| significativamente | 18 |
| retiro | 18 |
| protocolos | 18 |
| protocolo | 18 |
| presentaron | 18 |
| perfusión | 18 |
| unidades | 18 |
| marzo | 18 |
| final | 18 |
| manifestaciones | 18 |
| cambios | 18 |
| elementos | 18 |
| enfermos | 18 |
| duración | 18 |
| frente | 18 |
| fuera | 18 |
| hallazgos | 18 |
| hospitalización | 18 |
| Geleris | 17 |
| Scientific | 17 |
| Savarino | 17 |
| Pharmacologic | 17 |
| K. | 17 |
| Inhibition | 17 |
| IgG | 17 |
| Global | 17 |
| Clin | 17 |
| GS-441 | 17 |
| February | 17 |
| Europe | 17 |
| ELF | 17 |
| Corona | 17 |
| Characteristics | 17 |
| Cardiovascular | 17 |
| Acute | 17 |
| Torsades | 17 |
| aún | 17 |
| central | 17 |
| mediante | 17 |
| después | 17 |
| términos | 17 |
| sistema | 17 |
| seguimiento | 17 |
| reportaron | 17 |
| procesos | 17 |
| proceso | 17 |
| requieren | 17 |
| humano | 17 |
| fase | 17 |
| extubación | 17 |
| evaluación | 17 |
| esto | 17 |
| edad | 17 |
| general | 17 |
| doc_id | 17 |
| TLR7 | 16 |
| R. | 16 |
| RdRp | 16 |
| South | 16 |
| T. | 16 |
| Vincent | 16 |
| Treatments | 16 |
| Umifenovir | 16 |
| Viral | 16 |
| Noscapine | 16 |
| Province | 16 |
| CAD | 16 |
| Inhibitors | 16 |
| Impact | 16 |
| III | 16 |
| GS-5734 | 16 |
| GI | 16 |
| Force | 16 |
| E | 16 |
| CRB-65 | 16 |
| 3CL | 16 |
| capacidad | 16 |
| adecuada | 16 |
| Golgi | 16 |
| comparado | 16 |
| muy | 16 |
| complejidad | 16 |
| unidad | 16 |
| trabajadores | 16 |
| siempre | 16 |
| riesgos | 16 |
| reducir | 16 |
| prono | 16 |
| valoración | 16 |
| probabilidad | 16 |
| ningún | 16 |
| pruebas | 16 |
| intervenciones | 16 |
| implementación | 16 |
| hepatitis | 16 |
| hACE2 | 16 |
| ensayo | 16 |
| enfermedades | 16 |
| disponible | 16 |
| daño | 16 |
| contaminación | 16 |
| interleukin-6 | 16 |
| Preferred | 15 |
| Institutes | 15 |
| Japan | 15 |
| Ministry | 15 |
| Plasma | 15 |
| Washington | 15 |
| Series | 15 |
| Singh | 15 |
| Task | 15 |
| VMNI | 15 |
| HAMP | 15 |
| IL-1β | 15 |
| Accepted | 15 |
| H5N1 | 15 |
| 15 | |
| G6PD | 15 |
| Esto | 15 |
| Doxycycline | 15 |
| Development | 15 |
| Council | 15 |
| Chronic | 15 |
| Choudhary | 15 |
| Bazett | 15 |
| America | 15 |
| aPL | 15 |
| Xue | 15 |
| Toll | 15 |
| alteraciones | 15 |
| pointes | 15 |
| aplicación | 15 |
| ░ | 15 |
| μM | 15 |
| traqueostomía | 15 |
| torsades | 15 |
| tiempos | 15 |
| suficiente | 15 |
| rendimiento | 15 |
| recurso | 15 |
| realizaron | 15 |
| prednisone | 15 |
| posterior | 15 |
| situaciones | 15 |
| monitoreo | 15 |
| entrenamiento | 15 |
| bolsa | 15 |
| herramienta | 15 |
| cardiovascular | 15 |
| cardiovasculares | 15 |
| emitir | 15 |
| estancia | 15 |
| expertos | 15 |
| grave | 15 |
| hacer | 15 |
| Rhythm | 14 |
| JAK | 14 |
| Kg | 14 |
| OR | 14 |
| Patient | 14 |
| REM | 14 |
| aumentar | 14 |
| Systemic | 14 |
| Tabla | 14 |
| Y | 14 |
| asociados | 14 |
| biomarcadores | 14 |
| IVIG | 14 |
| Influenza | 14 |
| Animal | 14 |
| HMO | 14 |
| H. | 14 |
| Guangdong | 14 |
| FiO2 | 14 |
| Estos | 14 |
| E. | 14 |
| Dose | 14 |
| Critical | 14 |
| City | 14 |
| Chi | 14 |
| CA | 14 |
| Borba | 14 |
| Adjunctive | 14 |
| caso | 14 |
| cardiaca | 14 |
| mostró | 14 |
| condición | 14 |
| metas | 14 |
| contagio | 14 |
| β | 14 |
| þ | 14 |
| útil | 14 |
| áreas | 14 |
| ventilatorio | 14 |
| tratamientos | 14 |
| todo | 14 |
| temprana | 14 |
| rheumatoid | 14 |
| prevención | 14 |
| personas | 14 |
| nutrición | 14 |
| valores | 14 |
| están | 14 |
| hidroxicloroquina | 14 |
| datos | 14 |
| enfermería | 14 |
| equipos | 14 |
| exposición | 14 |
| ha | 14 |
| mental | 14 |
| inicial | 14 |
| inmunoglobulina | 14 |
| insuficiencia | 14 |
| intensivista | 14 |
| leve | 14 |
| NADPH | 13 |
| Plaquenil | 13 |
| NF | 13 |
| RMSD | 13 |
| chemoprophylaxis | 13 |
| Life | 13 |
| LC | 13 |
| Spike | 13 |
| Items | 13 |
| SS | 13 |
| Vina | 13 |
| Tang | 13 |
| TdP | 13 |
| Trump | 13 |
| U.S. | 13 |
| VA | 13 |
| analysis | 13 |
| aunque | 13 |
| IL-10 | 13 |
| Interleukin-6 | 13 |
| BF | 13 |
| ICD-10 | 13 |
| Centers | 13 |
| cuanto | 13 |
| A. | 13 |
| Africa | 13 |
| Anti | 13 |
| Arabia | 13 |
| BA | 13 |
| Baricitinib | 13 |
| Cardiology | 13 |
| Combination | 13 |
| HCQ+AZM | 13 |
| Commission | 13 |
| Coxiella | 13 |
| DIP | 13 |
| Diphosphate | 13 |
| Doses | 13 |
| Embase | 13 |
| Emergency | 13 |
| Esta | 13 |
| controles | 13 |
| demostrado | 13 |
| cánula | 13 |
| primeras | 13 |
| monocyte | 13 |
| n= | 13 |
| otro | 13 |
| paro | 13 |
| participantes | 13 |
| posibilidad | 13 |
| presentan | 13 |
| primera | 13 |
| profesionales | 13 |
| mcg | 13 |
| protectora | 13 |
| respecto | 13 |
| respirador | 13 |
| rápida | 13 |
| sanitario | 13 |
| saturación | 13 |
| terapéutico | 13 |
| vez | 13 |
| moderado | 13 |
| tórax | 13 |
| mayores | 13 |
| estar | 13 |
| mayo | 13 |
| directa | 13 |
| disfunción | 13 |
| doxycycline | 13 |
| ello | 13 |
| escalas | 13 |
| específico | 13 |
| específicos | 13 |
| descrito | 13 |
| esté | 13 |
| incluye | 13 |
| existe | 13 |
| limitaciones | 13 |
| investigación | 13 |
| mascarilla | 13 |
| incluidos | 13 |
| hospital | 13 |
| hay | 13 |
| GM | 12 |
| Trials | 12 |
| LPS | 12 |
| OATP1A2 | 12 |
| SSZ | 12 |
| Schrezenmeier | 12 |
| Sciences | 12 |
| Structure | 12 |
| ICMR | 12 |
| beneficios | 12 |
| Xu | 12 |
| años | 12 |
| basado | 12 |
| capacitación | 12 |
| catéter | 12 |
| choque | 12 |
| col | 12 |
| Ethics | 12 |
| combinación | 12 |
| G. | 12 |
| Coronaviruses | 12 |
| Erythematosus | 12 |
| Effectiveness | 12 |
| detección | 12 |
| ACE | 12 |
| B. | 12 |
| CC50 | 12 |
| CCAE | 12 |
| CSF | 12 |
| Calu-3 | 12 |
| CoV. | 12 |
| Complications | 12 |
| Convalescent | 12 |
| DC | 12 |
| DNA | 12 |
| EC50 | 12 |
| ELISA | 12 |
| ELs | 12 |
| EM | 12 |
| EP | 12 |
| definir | 12 |
| cohorte | 12 |
| diferencias | 12 |
| solución | 12 |
| primeros | 12 |
| procedimientos | 12 |
| progresión | 12 |
| pulmonares | 12 |
| qué | 12 |
| realiza | 12 |
| relación | 12 |
| resolución | 12 |
| supervivencia | 12 |
| nos | 12 |
| tasas | 12 |
| tracto | 12 |
| troponina | 12 |
| técnicas | 12 |
| van | 12 |
| | | 12 |
| documento | 12 |
| | 12 |
| orotraqueal | 12 |
| signos | 12 |
| ni | 12 |
| iniciar | 12 |
| escenarios | 12 |
| ng | 12 |
| forma | 12 |
| fármacos | 12 |
| genera | 12 |
| hace | 12 |
| hydroxyurea | 12 |
| inflamación | 12 |
| gravedad | 12 |
| líquidos | 12 |
| mL | 12 |
| marcadores | 12 |
| médicos | 12 |
| múltiples | 12 |
| institucional | 12 |
| negativa | 12 |
| negativos | 12 |
| Recommendations | 11 |
| Staphylococcus | 11 |
| U | 11 |
| Tf | 11 |
| Statistical | 11 |
| Saleh | 11 |
| Shi | 11 |
| Scholar | 11 |
| Recovery | 11 |
| abril | 11 |
| Zhou | 11 |
| arritmias | 11 |
| acceso | 11 |
| además | 11 |
| adicional | 11 |
| admisión | 11 |
| altas | 11 |
| alteración | 11 |
| aumenta | 11 |
| anticoagulación | 11 |
| artesunate | 11 |
| association | 11 |
| PP | 11 |
| President | 11 |
| Arbidol | 11 |
| PD-1 | 11 |
| Este | 11 |
| cardiaco | 11 |
| A2AR | 11 |
| ANOVA | 11 |
| Activation | 11 |
| Appendix | 11 |
| Asai | 11 |
| Attribution | 11 |
| Authorization | 11 |
| EMA | 11 |
| England | 11 |
| First | 11 |
| Nitazoxanide | 11 |
| HBPM | 11 |
| HCV | 11 |
| HRS | 11 |
| Indian | 11 |
| Iron | 11 |
| Italia | 11 |
| Kp | 11 |
| Medicina | 11 |
| N. | 11 |
| NEWS-2 | 11 |
| bioética | 11 |
| Lung | 11 |
| centro | 11 |
| p<0.0001 | 11 |
| patologías | 11 |
| permite | 11 |
| pesar | 11 |
| población | 11 |
| posible | 11 |
| prona | 11 |
| práctica | 11 |
| puntos | 11 |
| quienes | 11 |
| refractaria | 11 |
| relacionadas | 11 |
| respiración | 11 |
| segura | 11 |
| será | 11 |
| sobrevida | 11 |
| temprano | 11 |
| tenían | 11 |
| transfusión | 11 |
| tuvieron | 11 |
| técnica | 11 |
| umifenovir | 11 |
| ventilador | 11 |
| citocinas | 11 |
| papel | 11 |
| sarilumab | 11 |
| multicéntrico | 11 |
| fecha | 11 |
| mol | 11 |
| deberá | 11 |
| demostró | 11 |
| disnea | 11 |
| disponibles | 11 |
| dispositivos | 11 |
| elevados | 11 |
| eliminación | 11 |
| específica | 11 |
| esteroides | 11 |
| egreso | 11 |
| mejora | 11 |
| hemodinámica | 11 |
| i.p | 11 |
| identificar | 11 |
| lograr | 11 |
| línea | 11 |
| manos | 11 |
| miocárdica | 11 |
| ml | 11 |
| fiebre | 11 |
| mmHg | 11 |
| Kumar | 10 |
| JAMA | 10 |
| Kim | 10 |
| Hubei | 10 |
| Intervals | 10 |
| Lee | 10 |
| Intracellular | 10 |
| IA | 10 |
| Interferon | 10 |
| IgA | 10 |
| IR | 10 |
| IL-17 | 10 |
| NSAID | 10 |
| MEDLINE | 10 |
| Th17 | 10 |
| Nature | 10 |
| Pharmacogenomics | 10 |
| Postexposure | 10 |
| Protein | 10 |
| RPE | 10 |
| Rosenberg | 10 |
| S4 | 10 |
| SCCS | 10 |
| September | 10 |
| Sjogren | 10 |
| Support | 10 |
| adecuación | 10 |
| Haładyj | 10 |
| Horby | 10 |
| Angiotensin | 10 |
| HP | 10 |
| Cheng | 10 |
| AIPTW | 10 |
| AP | 10 |
| Alliance | 10 |
| ajustar | 10 |
| August | 10 |
| BCG | 10 |
| Bhubaneswar | 10 |
| Bioavailability | 10 |
| Boulware | 10 |
| CB | 10 |
| CYP3A5 | 10 |
| Caco-2 | 10 |
| Colombia | 10 |
| HCQ+ | 10 |
| Comparative | 10 |
| Con | 10 |
| Diagnosis | 10 |
| Dis | 10 |
| EEs | 10 |
| EUA | 10 |
| EULAR | 10 |
| Epidemiology | 10 |
| European | 10 |
| F. | 10 |
| Finalmente | 10 |
| G | 10 |
| aislamiento | 10 |
| Rheumatology | 10 |
| anti | 10 |
| predecir | 10 |
| metformin | 10 |
| modelos | 10 |
| monitoria | 10 |
| n.d | 10 |
| necesarios | 10 |
| oseltamivir | 10 |
| p= | 10 |
| paliativos | 10 |
| parámetros | 10 |
| peso | 10 |
| podrían | 10 |
| posibles | 10 |
| posteriores | 10 |
| puntaje | 10 |
| lugar | 10 |
| quien | 10 |
| recuperación | 10 |
| reportado | 10 |
| rhesus | 10 |
| secuelas | 10 |
| sistemas | 10 |
| situación | 10 |
| todas | 10 |
| área | 10 |
| éticos | 10 |
| óptimo | 10 |
| aparición | 10 |
| ≤ | 10 |
| marco | 10 |
| propone | 10 |
| intervención | 10 |
| asoció | 10 |
| author(s | 10 |
| intensidad | 10 |
| azitromicina | 10 |
| cadáver | 10 |
| características | 10 |
| comparación | 10 |
| componentes | 10 |
| considera | 10 |
| continuo | 10 |
| cuadro | 10 |
| células | 10 |
| desinfectante | 10 |
| confirmado | 10 |
| determinar | 10 |
| guías | 10 |
| impacto | 10 |
| diferencia | 10 |
| identificación | 10 |
| hubo | 10 |
| hacia | 10 |
| hospitales | 10 |
| generales | 10 |
| experiencia | 10 |
| encontraron | 10 |
| ellos | 10 |
| incluir | 10 |
| Sepsis | 9 |
| Springer | 9 |
| Potential | 9 |
| SD | 9 |
| SAEs | 9 |
| Response | 9 |
| Pulmonary | 9 |
| NOX | 9 |
| Population | 9 |
| PAFI | 9 |
| Network | 9 |
| NSAIDs | 9 |
| NFAT | 9 |
| TNFα | 9 |
| Malaria | 9 |
| TLR3 | 9 |
| citoquinas | 9 |
| acerca | 9 |
| administración | 9 |
| Lys31 | 9 |
| compararon | 9 |
| comorbilidades | 9 |
| clinicaltrials.gov | 9 |
| claro | 9 |
| cardiac | 9 |
| cambio | 9 |
| bloqueo | 9 |
| ausencia | 9 |
| asistencial | 9 |
| aquellos | 9 |
| antimaláricos | 9 |
| amoxicillin | 9 |
| alveolar | 9 |
| alerta | 9 |
| MAX | 9 |
| BAFF | 9 |
| Literature | 9 |
| Interim | 9 |
| Department | 9 |
| Delphi | 9 |
| D. | 9 |
| Corticosteroid | 9 |
| Centre | 9 |
| Cardiotoxicity | 9 |
| Cancer | 9 |
| Beijing | 9 |
| Americans | 9 |
| Agency | 9 |
| AIIMS | 9 |
| AIDS | 9 |
| A12 | 9 |
| 8) | 9 |
| continua | 9 |
| Dr. | 9 |
| EMBASE | 9 |
| Entry | 9 |
| His41 | 9 |
| Int | 9 |
| Information | 9 |
| IL-2 | 9 |
| IL-1 | 9 |
| ID | 9 |
| Hong | 9 |
| HBV | 9 |
| Epidemiological | 9 |
| H | 9 |
| Gao | 9 |
| GC | 9 |
| Furst | 9 |
| FBS | 9 |
| Expert | 9 |
| consenso | 9 |
| medicina | 9 |
| cuidado | 9 |
| monitorización | 9 |
| qSOFA | 9 |
| publicación | 9 |
| primero | 9 |
| primer | 9 |
| previamente | 9 |
| presentación | 9 |
| predictores | 9 |
| positivos | 9 |
| plan | 9 |
| ofrecer | 9 |
| observacional | 9 |
| novo | 9 |
| nervioso | 9 |
| nacional | 9 |
| mostraron | 9 |
| razonable | 9 |
| resistencia | 9 |
| rfIFN | 9 |
| trombosis | 9 |
| dados | 9 |
| último | 9 |
| índices | 9 |
| ésta | 9 |
| À1 | 9 |
| whipplei | 9 |
| tres | 9 |
| sintomatología | 9 |
| tomografía | 9 |
| terapéutica | 9 |
| tenía | 9 |
| telesalud | 9 |
| sulfate | 9 |
| sugieren | 9 |
| moral | 9 |
| temperatura | 9 |
| mejorar | 9 |
| formación | 9 |
| familia | 9 |
| estén | 9 |
| espontánea | 9 |
| especificidad | 9 |
| eficacia | 9 |
| efectividad | 9 |
| ebola | 9 |
| east | 9 |
| difícil | 9 |
| dexametasona | 9 |
| desinfección | 9 |
| definida | 9 |
| data | 9 |
| medida | 9 |
| darunavir | 9 |
| fenotipos | 9 |
| dímero | 9 |
| gasto | 9 |
| incremento | 9 |
| lymphopenia | 9 |
| liberación | 9 |
| historia | 9 |
| lactato | 9 |
| kappaB | 9 |
| inferior | 9 |
| infectados | 9 |
| interferon | 9 |
| huésped | 9 |
| incidencia | 9 |
| implementar | 9 |
| https://doi.org/10.1101 | 9 |
| https://doi.org/10.1101/2020.06.16.20132597 | 9 |
| incluso | 9 |
| Real | 8 |
| Picot | 8 |
| Portugal | 8 |
| Propofol | 8 |
| RMSE | 8 |
| Protease | 8 |
| RMSF | 8 |
| Rapid | 8 |
| Receptor | 8 |
| Pentoxifylline | 8 |
| Personalized | 8 |
| NT | 8 |
| PDB | 8 |
| PCA | 8 |
| P450 | 8 |
| Open | 8 |
| Non | 8 |
| Molina | 8 |
| Modeling | 8 |
| Michael | 8 |
| Mehra | 8 |
| Rheumatoid | 8 |
| Manejo | 8 |
| Republic | 8 |
| Wu | 8 |
| S6 | 8 |
| Tisdale | 8 |
| Lombardy | 8 |
| cerebral | 8 |
| capilar | 8 |
| broncoscopia | 8 |
| bioseguridad | 8 |
| bajos | 8 |
| b.i.d | 8 |
| Zhu | 8 |
| Whipple | 8 |
| W. | 8 |
| Therapeutic | 8 |
| SAS | 8 |
| Technology | 8 |
| Tables | 8 |
| TNF- | 8 |
| Síndrome | 8 |
| Social | 8 |
| Singapore | 8 |
| Shanghai | 8 |
| Salmonella | 8 |
| SI | 8 |
| SCT | 8 |
| Long | 8 |
| Cao | 8 |
| License | 8 |
| CTD | 8 |
| Covid | 8 |
| Cong | 8 |
| Comparison | 8 |
| Como | 8 |
| Chikungunya | 8 |
| Chemical | 8 |
| Chatre | 8 |
| Central | 8 |
| Canada | 8 |
| CVD | 8 |
| COV | 8 |
| LV | 8 |
| Background | 8 |
| Antimalarials | 8 |
| Andrea | 8 |
| Anakinra | 8 |
| Agents | 8 |
| AZT | 8 |
| AUC | 8 |
| AMSTAR | 8 |
| ACV | 8 |
| confirmados | 8 |
| DMARD | 8 |
| Dexamethasone | 8 |
| DisCoVeRy | 8 |
| Discovery | 8 |
| Kong | 8 |
| King | 8 |
| January | 8 |
| Iran | 8 |
| IL-8 | 8 |
| IL-7 | 8 |
| IL | 8 |
| I. | 8 |
| Huang | 8 |
| Hu | 8 |
| Guo | 8 |
| Fox | 8 |
| Febuxostat | 8 |
| Features | 8 |
| FV | 8 |
| Epub | 8 |
| Egypt | 8 |
| EU | 8 |
| EBOV | 8 |
| Dörner | 8 |
| Dynamics | 8 |
| colaboradores | 8 |
| kJ | 8 |
| contar | 8 |
| protein | 8 |
| rápidamente | 8 |
| respiradores | 8 |
| replicación | 8 |
| reciente | 8 |
| realizarse | 8 |
| quirúrgica | 8 |
| puedan | 8 |
| publicado | 8 |
| publicaciones | 8 |
| proteína | 8 |
| pronación | 8 |
| sean | 8 |
| profunda | 8 |
| procalcitonina | 8 |
| primario | 8 |
| primaquine | 8 |
| preoxigenación | 8 |
| positivo | 8 |
| patología | 8 |
| pSS | 8 |
| optimizar | 8 |
| obtener | 8 |
| sangre | 8 |
| segunda | 8 |
| nítrico | 8 |
| utilizados | 8 |
| controlado | 8 |
| ética | 8 |
| µM | 8 |
| vital | 8 |
| virologic | 8 |
| virales | 8 |
| ventilados | 8 |
| vena | 8 |
| vasculares | 8 |
| variabilidad | 8 |
| transmisión | 8 |
| serie | 8 |
| total | 8 |
| tormenta | 8 |
| tolerancia | 8 |
| sólo | 8 |
| superior | 8 |
| social | 8 |
| sobrevivientes | 8 |
| sobrecarga | 8 |
| significativo | 8 |
| series | 8 |
| objetivos | 8 |
| siguiendo | 8 |
| neurológicas | 8 |
| encefalitis | 8 |
| garantizar | 8 |
| frecuentes | 8 |
| frecuente | 8 |
| falta | 8 |
| evitando | 8 |
| estrés | 8 |
| estas | 8 |
| específicas | 8 |
| especiales | 8 |
| espacio | 8 |
| dolor | 8 |
| hemodinámico | 8 |
| doi | 8 |
| disposición | 8 |
| didanosine | 8 |
| describieron | 8 |
| desarrollo | 8 |
| derechos | 8 |
| demanda | 8 |
| dar | 8 |
| correlación | 8 |
| negativas | 8 |
| grado | 8 |
| efectiva | 8 |
| hydroxyferroquine | 8 |
| óxido | 8 |
| necesaria | 8 |
| igual | 8 |
| mínimo | 8 |
| muestran | 8 |
| muerte | 8 |
| modalidades | 8 |
| medio | 8 |
| mecanismos | 8 |
| limpieza | 8 |
| laboratorio | 8 |
| medicamento | 8 |
| ingresados | 8 |
| institucionales | 8 |
| isquémico | 8 |
| indirecta | 8 |
| inflamatorios | 8 |
| iniciales | 8 |
| incluyeron | 8 |
| intensivistas | 8 |
| interferón | 8 |
| intravenosa | 8 |
| OHDSI | 7 |
| Paris | 7 |
| October | 7 |
| Optum | 7 |
| POCUS | 7 |
| PS | 7 |
| QSAR | 7 |
| Pharmacological | 7 |
| Perinel | 7 |
| Pharmacol | 7 |
| Que | 7 |
| Pulmonar | 7 |
| Newcastle | 7 |
| North | 7 |
| Magagnoli | 7 |
| Neutrophil | 7 |
| NK | 7 |
| NH | 7 |
| Model | 7 |
| Methotrexate | 7 |
| Mercuro | 7 |
| Medicines | 7 |
| Mauthe | 7 |
| Material | 7 |
| Massachusetts | 7 |
| M1 | 7 |
| Lu | 7 |
| SARS‐CoV‐2 | 7 |
| Lim | 7 |
| RAS | 7 |
| aspectos | 7 |
| SIGN | 7 |
| SNPs | 7 |
| LR | 7 |
| buena | 7 |
| bien | 7 |
| avanzada | 7 |
| autores | 7 |
| ataque | 7 |
| artículos | 7 |
| antivirales | 7 |
| anterior | 7 |
| altos | 7 |
| alternativa | 7 |
| agua | 7 |
| agentes | 7 |
| adecuadamente | 7 |
| actividades | 7 |
| Yan | 7 |
| X | 7 |
| Ventilation | 7 |
| V | 7 |
| Tropheryma | 7 |
| TRPML1 | 7 |
| TLRs | 7 |
| Synthesis | 7 |
| Sun | 7 |
| Strategies | 7 |
| Sheahan | 7 |
| Sci | 7 |
| LTCF | 7 |
| Asinex | 7 |
| JT | 7 |
| Baseline | 7 |
| DRV | 7 |
| DE | 7 |
| Cytokines | 7 |
| Ct | 7 |
| Controlled | 7 |
| Conti | 7 |
| Consensus | 7 |
| Choy | 7 |
| Camostat | 7 |
| CYP1B1 | 7 |
| CPRD | 7 |
| CME | 7 |
| CD154 | 7 |
| Balayla | 7 |
| Italian | 7 |
| BMI | 7 |
| Aunque | 7 |
| causas | 7 |
| Arshad | 7 |
| Antibody | 7 |
| Analyses | 7 |
| Akt | 7 |
| Ahmad | 7 |
| Advisory | 7 |
| Adult | 7 |
| ATE | 7 |
| AMX | 7 |
| A2 | 7 |
| David | 7 |
| Dependent | 7 |
| Devaux | 7 |
| Di | 7 |
| Interventions | 7 |
| Immune | 7 |
| IPT | 7 |
| ICMJE | 7 |
| Host | 7 |
| Hopkins | 7 |
| Hoffmann | 7 |
| Histoplasma | 7 |
| Helsinki | 7 |
| HCoV-229E | 7 |
| HCQS | 7 |
| Goldman | 7 |
| Galidesivir | 7 |
| Forest | 7 |
| Fisher | 7 |
| Findings | 7 |
| FCoV | 7 |
| Exposure | 7 |
| Existe | 7 |
| Event | 7 |
| Editor | 7 |
| Echocardiography | 7 |
| EMR | 7 |
| EMBO | 7 |
| Dímero | 7 |
| Doi | 7 |
| Director | 7 |
| camostat | 7 |
| Sinha | 7 |
| centros | 7 |
| nasofaríngeo | 7 |
| presenten | 7 |
| presentar | 7 |
| pq10 | 7 |
| potencialmente | 7 |
| persistente | 7 |
| paso | 7 |
| pasiva | 7 |
| paliativo | 7 |
| paliativa | 7 |
| orgánica | 7 |
| neuromyopathy | 7 |
| neuromuscular | 7 |
| necesidades | 7 |
| múltiple | 7 |
| principios | 7 |
| máscara | 7 |
| murieron | 7 |
| multiorgánica | 7 |
| moderada | 7 |
| modelo | 7 |
| mismo | 7 |
| min | 7 |
| mg/2 | 7 |
| metilprednisolona | 7 |
| metaanálisis | 7 |
| mesylate | 7 |
| membrana | 7 |
| medir | 7 |
| prevenir | 7 |
| profilaxis | 7 |
| literatura | 7 |
| sospechar | 7 |
| cerebro | 7 |
| índice | 7 |
| ¼ | 7 |
| vasopresor | 7 |
| varias | 7 |
| utilizando | 7 |
| utilidad | 7 |
| trastornos | 7 |
| trans | 7 |
| tisular | 7 |
| terapias | 7 |
| superioridad | 7 |
| st | 7 |
| simplex | 7 |
| pulmón | 7 |
| significativas | 7 |
| semana | 7 |
| secundaria | 7 |
| sala | 7 |
| resultado | 7 |
| respiratorias | 7 |
| respectivamente | 7 |
| resonancia | 7 |
| relacionados | 7 |
| referencia | 7 |
| realizada | 7 |
| reacciones | 7 |
| pulso | 7 |
| material | 7 |
| realizó | 7 |
| linfocitos | 7 |
| desafíos | 7 |
| factor | 7 |
| expansión | 7 |
| examen | 7 |
| estadísticamente | 7 |
| escasez | 7 |
| epidemia | 7 |
| elección | 7 |
| ecografía | 7 |
| documentado | 7 |
| disminuye | 7 |
| diagnóstica | 7 |
| destete | 7 |
| desarrollaron | 7 |
| corticoides | 7 |
| familiares | 7 |
| corriente | 7 |
| convencional | 7 |
| conocimiento | 7 |
| confusión | 7 |
| confirmación | 7 |
| comunidad | 7 |
| comunicación | 7 |
| compliance | 7 |
| complemento | 7 |
| combinado | 7 |
| colocación | 7 |
| limitación | 7 |
| cinco | 7 |
| falsos | 7 |
| decidir | 7 |
| fases | 7 |
| hisopado | 7 |
| lesiones | 7 |
| le | 7 |
| fenotipo | 7 |
| intubados | 7 |
| inmune | 7 |
| ingresan | 7 |
| inducido | 7 |
| individuos | 7 |
| indicación | 7 |
| incluyó | 7 |
| incluyen | 7 |
| i.v | 7 |
| https://doi.org/10.1101/2020.05.02.20088872 | 7 |
| hospitalario | 7 |
| indicaciones | 7 |
| generación | 7 |
| hiperinmune | 7 |
| higiene | 7 |
| herpes | 7 |
| heparina | 7 |
| haga | 7 |
| guiar | 7 |
| graves | 7 |
| generador | 7 |
| fluidos | 7 |
| fracaso | 7 |
| ferritina | 7 |
| Score | 6 |
| Scopus | 6 |
| Sarma | 6 |
| Step | 6 |
| San | 6 |
| STROBE | 6 |
| ST | 6 |
| Section | 6 |
| Software | 6 |
| Service | 6 |
| Shukla | 6 |
| Silva | 6 |
| Structural | 6 |
| Stata | 6 |
| Statement | 6 |
| Stockpile | 6 |
| Ribavirin | 6 |
| SJS | 6 |
| PSM | 6 |
| Resource | 6 |
| Pharmacology | 6 |
| Oseltamivir | 6 |
| Outbreak | 6 |
| Supplemental | 6 |
| P | 6 |
| PNT | 6 |
| PO | 6 |
| Pero | 6 |
| Phase | 6 |
| Registry | 6 |
| Polymerase | 6 |
| Prolongation | 6 |
| QTcFrh | 6 |
| Quality | 6 |
| RD | 6 |
| ROBINS | 6 |
| ROS | 6 |
| Sulfate | 6 |
| basada | 6 |
| Surviving | 6 |
| base | 6 |
| alfa | 6 |
| algunas | 6 |
| alguno | 6 |
| ambos | 6 |
| anosmia | 6 |
| aplicar | 6 |
| bacteriana | 6 |
| cabecera | 6 |
| TCID | 6 |
| cava | 6 |
| cefalea | 6 |
| celulosa | 6 |
| cercano | 6 |
| china | 6 |
| OMS | 6 |
| circuito | 6 |
| aleatorizado | 6 |
| ajustado | 6 |
| administration | 6 |
| adecuadas | 6 |
| TM | 6 |
| TS | 6 |
| Taiwan | 6 |
| Term | 6 |
| Testing | 6 |
| Therapeutics | 6 |
| Thomas | 6 |
| Transmission | 6 |
| Ultrasound | 6 |
| V. | 6 |
| Ventricular | 6 |
| White | 6 |
| Wilde | 6 |
| Y. | 6 |
| acción | 6 |
| ORCHID | 6 |
| COVID- | 6 |
| OD | 6 |
| Cuando | 6 |
| Chest | 6 |
| Children | 6 |
| CloroCovid-19 | 6 |
| Computing | 6 |
| Coronaviridae | 6 |
| Cov | 6 |
| Critically | 6 |
| DM | 6 |
| Federal | 6 |
| DMEM | 6 |
| Database | 6 |
| Detection | 6 |
| Docking | 6 |
| EPOC | 6 |
| ERK | 6 |
| Effects | 6 |
| Chemoprophylaxis | 6 |
| Cardiol | 6 |
| Caly | 6 |
| CRRT | 6 |
| ciudad | 6 |
| -2 | 6 |
| APL | 6 |
| Abdullah | 6 |
| Access | 6 |
| Además | 6 |
| Alexander | 6 |
| Arrhythmias | 6 |
| Asia | 6 |
| BACKGROUND | 6 |
| BFLA1 | 6 |
| Barcelona | 6 |
| Benefit | 6 |
| Bias | 6 |
| CAP | 6 |
| Electronic | 6 |
| Gilead | 6 |
| Nutrition | 6 |
| NHIS | 6 |
| MA | 6 |
| MLR | 6 |
| MOA | 6 |
| Madrid | 6 |
| McChesney | 6 |
| Ministerio | 6 |
| Multicenter | 6 |
| NIV | 6 |
| GraphPad | 6 |
| NOX2 | 6 |
| NSCLC | 6 |
| NZ | 6 |
| Na | 6 |
| Nafamostat | 6 |
| Neurological | 6 |
| Nipah | 6 |
| Lan | 6 |
| Laboratory | 6 |
| LTEC | 6 |
| Kingdom | 6 |
| HTN | 6 |
| Hasta | 6 |
| ICD-8 | 6 |
| ID-19 | 6 |
| IRA | 6 |
| Identification | 6 |
| Inhibitor | 6 |
| Injury | 6 |
| Intensiva | 6 |
| Involvement | 6 |
| Janus | 6 |
| Johns | 6 |
| Johnson | 6 |
| Kaplan | 6 |
| Keyaerts | 6 |
| circunstancias | 6 |
| lM | 6 |
| clara | 6 |
| pueda | 6 |
| previo | 6 |
| principalmente | 6 |
| producir | 6 |
| profesional | 6 |
| promover | 6 |
| proporción | 6 |
| publicaron | 6 |
| pública | 6 |
| presentó | 6 |
| radiografía | 6 |
| razón | 6 |
| reclutamiento | 6 |
| rehabilitación | 6 |
| relacionado | 6 |
| reportados | 6 |
| reporte | 6 |
| presiones | 6 |
| predicción | 6 |
| necesitan | 6 |
| oxigenoterapia | 6 |
| nitazoxanide | 6 |
| norepinefrina | 6 |
| noscapine | 6 |
| nutricional | 6 |
| núcleo | 6 |
| orientar | 6 |
| origen | 6 |
| p38 | 6 |
| pp1a | 6 |
| perfil | 6 |
| permita | 6 |
| plasmacytoid | 6 |
| plazo | 6 |
| pocos | 6 |
| podrá | 6 |
| positiva | 6 |
| reportes | 6 |
| requerimiento | 6 |
| requerimientos | 6 |
| venosa | 6 |
| tratar | 6 |
| usar | 6 |
| utilizarse | 6 |
| valor | 6 |
| varios | 6 |
| vasopresina | 6 |
| vasopresores | 6 |
| ventaja | 6 |
| requirieron | 6 |
| ventilatoria | 6 |
| vista | 6 |
| zona | 6 |
| × | 6 |
| éxito | 6 |
| clasificación | 6 |
| κB | 6 |
| tras | 6 |
| totalidad | 6 |
| titulación | 6 |
| tercera | 6 |
| reserva | 6 |
| retrospectiva | 6 |
| ruxolitinib | 6 |
| sanitarios | 6 |
| secundario | 6 |
| secundarios | 6 |
| sera | 6 |
| sospechoso | 6 |
| sulfonylureas | 6 |
| superficies | 6 |
| suplementario | 6 |
| séptico | 6 |
| tabla | 6 |
| talento | 6 |
| tenga | 6 |
| neurológicos | 6 |
| t.i.d | 6 |
| nasales | 6 |
| dl | 6 |
| desenlace | 6 |
| desinfectar | 6 |
| df | 6 |
| dipyridamole | 6 |
| directrices | 6 |
| distribución | 6 |
| diálisis | 6 |
| ecocardiografía | 6 |
| estabilidad | 6 |
| elastoméricos | 6 |
| elevado | 6 |
| enfoque | 6 |
| enteral | 6 |
| epilépticas | 6 |
| esfuerzo | 6 |
| espectro | 6 |
| describen | 6 |
| desaturación | 6 |
| derecho | 6 |
| der | 6 |
| coagulopatía | 6 |
| nafamostat | 6 |
| compasivo | 6 |
| completa | 6 |
| conciencia | 6 |
| considerado | 6 |
| considerados | 6 |
| contacto | 6 |
| contrario | 6 |
| convulsiones | 6 |
| coronaviruses | 6 |
| corte | 6 |
| cremación | 6 |
| cuadros | 6 |
| da | 6 |
| estaban | 6 |
| corto | 6 |
| establece | 6 |
| mejoraron | 6 |
| integral | 6 |
| interdependencia | 6 |
| interna | 6 |
| legal | 6 |
| limitada | 6 |
| limitar | 6 |
| manipulación | 6 |
| middle | 6 |
| inhalado | 6 |
| miocarditis | 6 |
| modo | 6 |
| molecular | 6 |
| morbilidad | 6 |
| establecido | 6 |
| muerto | 6 |
| máscaras | 6 |
| inhibir | 6 |
| cm | 6 |
| inflamatorias | 6 |
| global | 6 |
| excepto | 6 |
| establecidos | 6 |
| estructura | 6 |
| incluya | 6 |
| fibrinógeno | 6 |
| formas | 6 |
| generan | 6 |
| generar | 6 |
| fracción | 6 |
| green | 6 |
| hipotensión | 6 |
| hipoxia | 6 |
| importantes | 6 |
| habían | 6 |
| idealmente | 6 |
| PPT1 | 5 |
| Program | 5 |
| Position | 5 |
| Poole | 5 |
| PfDHFR | 5 |
| Page | 5 |
| People | 5 |
| Pathway | 5 |
| Patel | 5 |
| Prophylactic | 5 |
| Properties | 5 |
| RC | 5 |
| Protocol | 5 |
| Public | 5 |
| Pujol | 5 |
| QTcH | 5 |
| RBM | 5 |
| PICALM | 5 |
| RCP | 5 |
| RECOVERY | 5 |
| RaTG13 | 5 |
| Raoult | 5 |
| Recomendaciones | 5 |
| Related | 5 |
| Ribavirina | 5 |
| PMSI | 5 |
| OXA | 5 |
| Oxford | 5 |
| NAADP | 5 |
| Malek | 5 |
| Maisonnasse | 5 |
| Rolain | 5 |
| Marc | 5 |
| Martínez | 5 |
| Meier | 5 |
| MiSeq | 5 |
| Mice | 5 |
| Mitja | 5 |
| Moderate | 5 |
| Mohammed | 5 |
| NCT04308668 | 5 |
| Ovid | 5 |
| NCT04318444 | 5 |
| NL63 | 5 |
| NP | 5 |
| Nationale | 5 |
| Nrf2 | 5 |
| ONi | 5 |
| Optimization | 5 |
| Oral | 5 |
| Organización | 5 |
| Otro | 5 |
| Ottawa | 5 |
| Munster | 5 |
| Yi | 5 |
| Royal | 5 |
| Russia | 5 |
| Tipo | 5 |
| Treg | 5 |
| Trias | 5 |
| Van | 5 |
| Veterans | 5 |
| WBC | 5 |
| Zanella | 5 |
| Zhejiang | 5 |
| _ | 5 |
| acciones | 5 |
| actualmente | 5 |
| adaptadas | 5 |
| administrativos | 5 |
| administró | 5 |
| admitidos | 5 |
| adversas | 5 |
| alcanzar | 5 |
| aleatorios | 5 |
| aleatorización | 5 |
| aleatorizados | 5 |
| alguna | 5 |
| ambiente | 5 |
| ampliamente | 5 |
| MOIs | 5 |
| anatomía | 5 |
| Thoracic | 5 |
| Ther | 5 |
| Thanh | 5 |
| Shock | 5 |
| SAE | 5 |
| SAR | 5 |
| SEM | 5 |
| SIDIAP | 5 |
| SOLIDARITY | 5 |
| SPSS | 5 |
| STEMI | 5 |
| SVRI | 5 |
| SaO2 | 5 |
| Sanders | 5 |
| Second | 5 |
| Siddiqui | 5 |
| Tett | 5 |
| Sperber | 5 |
| Strategic | 5 |
| Stroke | 5 |
| TC1 | 5 |
| TEP | 5 |
| TFR1 | 5 |
| TGN | 5 |
| THP-1 | 5 |
| TNFa | 5 |
| TZ | 5 |
| También | 5 |
| Mahévas | 5 |
| Brain | 5 |
| MM | 5 |
| COPD | 5 |
| Bayes | 5 |
| Bayesian | 5 |
| Beaumont | 5 |
| Beigel | 5 |
| Belgium | 5 |
| Binding | 5 |
| Borne | 5 |
| CAF | 5 |
| CDDP | 5 |
| CENTRAL | 5 |
| CKD | 5 |
| COVD-19 | 5 |
| BNP | 5 |
| CPR | 5 |
| CV | 5 |
| CYP450 | 5 |
| Calleja | 5 |
| Campaign | 5 |
| Castelnuovo | 5 |
| Chan | 5 |
| Chemistry | 5 |
| Chicago | 5 |
| Choi | 5 |
| Chorin | 5 |
| Barbosa | 5 |
| BAL | 5 |
| CoV-2/ | 5 |
| Actualmente | 5 |
| anticipadas | 5 |
| 3a | 5 |
| A5 | 5 |
| AAG | 5 |
| AAK1 | 5 |
| ATP | 5 |
| Abbott | 5 |
| Abdulaziz | 5 |
| Academy | 5 |
| Acidotropic | 5 |
| Ackerman | 5 |
| Adenosine | 5 |
| Atención | 5 |
| Adverse | 5 |
| Alicante | 5 |
| Andersen | 5 |
| Andreani | 5 |
| Ante | 5 |
| Antibiotics | 5 |
| Application | 5 |
| Arnold | 5 |
| Arrhythmic | 5 |
| Artemisia | 5 |
| Artemisinin | 5 |
| Clearance | 5 |
| Collaboration | 5 |
| MI | 5 |
| Interactions | 5 |
| Gupta | 5 |
| HCQ+AZI | 5 |
| HNF | 5 |
| Henry | 5 |
| Hung | 5 |
| ICD | 5 |
| IL-12 | 5 |
| IL-18 | 5 |
| IL-6R | 5 |
| Illumina | 5 |
| Immunity | 5 |
| Investigational | 5 |
| Gattinoni | 5 |
| Jean | 5 |
| Jun | 5 |
| Kidney | 5 |
| LAC | 5 |
| Lassa | 5 |
| Le | 5 |
| Log | 5 |
| Lys353 | 5 |
| MATE1 | 5 |
| MCP-3 | 5 |
| MEM | 5 |
| Germans | 5 |
| GISAID | 5 |
| Colson | 5 |
| EKG | 5 |
| Contact | 5 |
| County | 5 |
| Cryo | 5 |
| Cryptococcus | 5 |
| Cys145 | 5 |
| Cytokine | 5 |
| Da | 5 |
| Declaration | 5 |
| Den | 5 |
| Diabetes | 5 |
| DoB | 5 |
| EPI | 5 |
| Francisella | 5 |
| ESI | 5 |
| Environment | 5 |
| Escherichia | 5 |
| FIO2 | 5 |
| Facilities | 5 |
| Failure | 5 |
| Fase | 5 |
| Favlplravir | 5 |
| Fe | 5 |
| Framingham | 5 |
| Francia | 5 |
| anticipada | 5 |
| recomiendan | 5 |
| aprobados | 5 |
| prolongada | 5 |
| pharmacokinetics | 5 |
| piel | 5 |
| placebo | 5 |
| plantea | 5 |
| poder | 5 |
| porque | 5 |
| pp1ab | 5 |
| precauciones | 5 |
| preguntas | 5 |
| previos | 5 |
| programa | 5 |
| promedio | 5 |
| percutánea | 5 |
| proporcionar | 5 |
| prospectivo | 5 |
| psicológica | 5 |
| racemate | 5 |
| realizado | 5 |
| realizan | 5 |
| recambio | 5 |
| receptor | 5 |
| recibir | 5 |
| reclutabilidad | 5 |
| recolección | 5 |
| período | 5 |
| participación | 5 |
| relaciona | 5 |
| multimodal | 5 |
| mencionados | 5 |
| menores | 5 |
| meses | 5 |
| mesilate | 5 |
| metodología | 5 |
| minimizar | 5 |
| mm | 5 |
| modalidad | 5 |
| monitorizar | 5 |
| mostrado | 5 |
| movilización | 5 |
| mundial | 5 |
| parece | 5 |
| máximo | 5 |
| mínima | 5 |
| neurológico | 5 |
| normales | 5 |
| nuevo | 5 |
| observacionales | 5 |
| opciones | 5 |
| oportuna | 5 |
| oral | 5 |
| orden | 5 |
| organización | 5 |
| redujo | 5 |
| relacionada | 5 |
| mass | 5 |
| ver | 5 |
| tromboprofilaxis | 5 |
| tularensis | 5 |
| tuvo | 5 |
| ultrasonido | 5 |
| unión | 5 |
| unos | 5 |
| valorar | 5 |
| vasoactivo | 5 |
| ventiladores | 5 |
| ventilatorias | 5 |
| ventrículo | 5 |
| voluntad | 5 |
| trabajos | 5 |
| volúmenes | 5 |
| µL | 5 |
| ¿ | 5 |
| éticas | 5 |
| órganos | 5 |
| últimos | 5 |
| γ | 5 |
| μg | 5 |
| σ | 5 |
| ∆ | 5 |
| arbidol | 5 |
| tratante | 5 |
| tomadas | 5 |
| reportan | 5 |
| seguro | 5 |
| representa | 5 |
| requerido | 5 |
| responsable | 5 |
| retroalimentación | 5 |
| ribavirina | 5 |
| rigor | 5 |
| rutinario | 5 |
| rápido | 5 |
| score | 5 |
| secreciones | 5 |
| segundo | 5 |
| selección | 5 |
| toda | 5 |
| servicio | 5 |